With its IPO, Cumberland Pharmaceuticals becomes Nashville’s second publicly traded biotechnology company. (BioMimetic Therapeutics went public three years earlier.)

Chairman and CEO A.J. Kazimi, who founded the company with $2 million ten years earlier, leads the IPO which generates $85 million.